G. Robinet

Centre Hospitalier Régional Universitaire de Brest — France

Medicine · Health Sciences

34h-index14.2kcitations192works13.52yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(120), Lung Cancer Research Studies(80), Lung Cancer Diagnosis and Treatment(35), Cancer Immunotherapy and Biomarkers(32), Brain Metastases and Treatment(25)

Publications188 total

EORTC 1417 - REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer
European Journal of Cancer·2025
Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced <i>EGFR</i>-Mutant Non–Small-Cell Lung Cancer
Journal of Clinical Oncology·2024· 27 citedOpen Access
Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1
Annals of Oncology·2023· 58 citedOpen Access
Appendix Methods and Materials, Tables 1-4, Figures 1-3 from Bevacizumab in Patients with Nonsquamous Non–Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study
2023Open Access
Appendix Methods and Materials, Tables 1-4, Figures 1-3 from Bevacizumab in Patients with Nonsquamous Non–Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study
2023Open Access
Supplementary Table S1 from Bevacizumab in Patients with Nonsquamous Non–Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study
2023Open Access
Data from Bevacizumab in Patients with Nonsquamous Non–Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study
2023Open Access
Supplementary Table S1 from Bevacizumab in Patients with Nonsquamous Non–Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study
2023Open Access
Data from Bevacizumab in Patients with Nonsquamous Non–Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study
2023Open Access
Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial
Annals of Oncology·2023· 66 citedOpen Access
Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer: An open-label phase II trial (VinMetAtezo)
Lung Cancer·2023· 8 cited
Pembrolizumab plus pemetrexed-carboplatin combination in first-line treatment of advanced non-squamous non-small cell lung cancer: a multicenter real-life study (CAP29)
Translational Lung Cancer Research·2023· 9 citedOpen Access
Real‐life second‐line epirubicin–paclitaxel regimen as treatment of relapsed small‐cell lung cancer: EpiTax study
Cancer Medicine·2022· 6 citedOpen Access
Real-life experience of rare hepatoid adenocarcinomas of the lung: A large retrospective french cohort.
Journal of Clinical Oncology·2022
366 Combined exploratory immunophenotyping and transcriptomic tumor analysis in patients treated with OSE2101 vaccine in HLA-A2+ advanced non-small cell lung cancer (NSCLC) from the ATALANTE-1 trial
Regular and Young Investigator Award Abstracts·2021Open Access
Management of patients with synchronous head-and-neck and lung cancers
Journal of Cancer Research and Therapeutics·2021· 5 citedOpen Access
71P Searching for predictive biomarkers of efficacy in small cell lung cancer (SCLC) patients treated with chemotherapy-immunotherapy combination using imaging mass cytometry (the HYPE study)
Annals of Oncology·2021· 4 cited
First-Line Pembrolizumab with or Without Platinum Doublet Chemotherapy in Non-Small-Cell Lung Cancer Patients with PD-L1 Expression ≥50%
Future Oncology·2021· 15 cited
Vascular Acrosyndromes Associated With Prolonged Tumor Response in Advanced Lung Cancer Patients During Treatment With Antimetabolites: A Report of Two Cases
Frontiers in Oncology·2021· 3 citedOpen Access
A Phase 1–2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC
Journal of Thoracic Oncology·2021· 76 citedOpen Access
page 1 of 10Next →

Frequent Co-authors

C. Chouaïd(16), A. Vergnenègre(15), Fabrice Barlési(12), P. Fournel(12), M. Pérol(11), H. Léna(10), Julien Mazières(9), P. Thomas(9), H. Léna(8), H. Bérard(8), I. Monnet(8), Benjamin Besse(7), H. Le Caer(7), Radj Gervais(6), D. Paillotin(6), L. Falchero(6), R. Descourt(6), Manuel Cobo(5), Éric Dansin(5), Nathalie Baize(5)